# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Femasys, Inc., (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide wit...
- Reuters
Chardan Capital analyst Keay Nakae maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $12 to $10.
HC Wainwright & Co. analyst Emily Bodnar maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $13...